SAB BiotherapeuticsSABS
About: SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Employees: 63
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
19% more capital invested
Capital invested by funds: $8.48M [Q3] → $10.1M (+$1.62M) [Q4]
0% more funds holding
Funds holding: 25 [Q3] → 25 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
5.56% less ownership
Funds ownership: 34.04% [Q3] → 28.48% (-5.56%) [Q4]
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Chardan Capital Keay Nakae 13% 1-year accuracy 9 / 72 met price target | 1,289%upside $20 | Buy Maintained | 1 Apr 2025 |
HC Wainwright & Co. Edward White 24% 1-year accuracy 36 / 149 met price target | 317%upside $6 | Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion









